Designing HIV-1 protease inhibitors that overcome drug-resistance is still a challenging task. In this study, four clinical isolates of multi-drug resistant HIV-1 proteases that exhibit resistance to all the US FDA-approved HIV-1 protease inhibitors and also reduce the substrate recognition ability were examined. A multi-drug resistant HIV-1 protease isolate, MDR 769, was co-crystallized with the p2/NC substrate and the mutated CA/p2 substrate, CA/p2 P1’F. Both substrates display different levels of molecular recognition by the wild-type and multi-drug resistant HIV-1 protease. From the crystal structures, only limited differences can be identified between the wild-type and multi-drug resistant protease. Therefore, a wild-type HIV-1 protease and four multi-drug resistant HIV-1 proteases in complex with the two peptides were modeled based on the crystal structures and examined during a 10 ns-molecular dynamics simulation. The simulation results reveal that the multi-drug resistant HIV-1 proteases require higher desolvation energy to form complexes with the peptides. This result suggests that the desolvation of the HIV-1 protease active site is an important step of protease-ligand complex formation as well as drug resistance. Therefore, desolvation energy could be considered as a parameter in the evaluation of future HIV-1 protease inhibitor candidates.
References
[1]
Nalam, M.N.L.; Ali, A.; Altman, M.D.; Reddy, G.S.K.K.; Chellappan, S.; Kairys, V.; Ozen, A.; Cao, H.; Gilson, M.K.; Tidor, B.; Rana, T.M.; Schiffer, C.A. Evaluating the substrate-envelope hypothesis: Structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance. J. Virol. 2010, 84, 5368–5378.
[2]
Prabu-Jeyabalan, M.; Schiffer, C.A.; Nalivaika, E. Substrate shape determines specificity of recognition for HIV-1 protease: Analysis of crystal structures of six substrate complexes. Structure 2002, 10, 369–381, doi:10.1016/S0969-2126(02)00720-7.
[3]
Ozen, A.; Haliloglu, T.; Schiffer, C.A. Dynamics of preferential substrate recognition in HIV-1 protease: Redefining the substrate envelope. J. Mol. Biol. 2011, 410, 726–744, doi:10.1016/j.jmb.2011.03.053.
[4]
Luque, I.; Todd, M.J.; Gomez, J.; Semo, N.; Freire, E. Molecular basis of resistance to HIV-1 protease inhibition: A plausible hypothesis. Biochemistry 1998, 37, 5791–5797.
[5]
Tie, Y.; Boross, P.I.; Wang, Y.F.; Gaddis, L.; Liu, F.; Chen, X.; Tozser, J.; Harrison, R.W.; Weber, I.T. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs. FEBS J. 2005, 272, 5265–5277.
[6]
Ohtaka, H.; Freire, E. Adaptive inhibitors of the HIV-1 protease. Prog. Biophys. Mol. Biol. 2005, 88, 193–208, doi:10.1016/j.pbiomolbio.2004.07.005.
[7]
Palmer, S.; Shafer, R.W.; Merigan, T.C. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS 1999, 13, 661–667.
[8]
Wang, Y.; Liu, Z.; Brunzelle, J.S.; Kovari, I.A.; Dewdney, T.G.; Reiter, S.J.; Kovari, L.C. The higher barrier of darunavir and tipranavir resistance for HIV-1 protease. Biochem. Biophys. Res. Commun. 2011, 412, 737–742, doi:10.1016/j.bbrc.2011.08.045.
[9]
Logsdon, B.C.; Vickrey, J.F.; Martin, P.; Proteasa, G.; Koepke, J.I.; Terlecky, S.R.; Wawrzak, Z.; Winters, M.A.; Merigan, T.C.; Kovari, L.C. Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity. J. Virol. 2004, 78, 3123–3132.
[10]
Vondrasek, J.; Wlodawer, A. HIVdb: A database of the structures of human immunodeficiency virus protease. Proteins 2002, 49, 429–431, doi:10.1002/prot.10246.
[11]
HHS. Panel on Antiretroviral Guidelines for Adults and Adolescents, Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents; Department of Health and Human Services: Washington, DC, USA, 2011.
[12]
Ozer, N.; Schiffer, C.A.; Haliloglu, T. Rationale for more diverse inhibitors in competition with substrates in HIV-1 protease. Biophys. J. 2010, 99, 1650–1659, doi:10.1016/j.bpj.2010.06.064.
[13]
Szeltner, Z.; Polgar, L. Rate-determining steps in HIV-1 protease catalysis - The hydrolysis of the most specific substrate. J. Bio.l Chem. 1996, 271, 32180–32184, doi:10.1074/jbc.271.50.32180.
[14]
Pettit, S.C.; Moody, M.D.; Wehbie, R.S.; Kaplan, A.H.; Nantermet, P.V.; Klein, C.A.; Swanstrom, R. The P2 domain of human-immunodeficiency-virus Type-1 gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J. Virol. 1994, 68, 8017–8027.
[15]
Vickrey, J.F.; Logsdon, B.C.; Proteasa, G.; Palmer, S.; Winters, M.A.; Merigan, T.C.; Kovari, L.C. HIV-1 protease variants from 100-fold drug resistant clinical isolates: Expression, purification, and crystallization. Protein Expr. Purif. 2003, 28, 165–172, doi:10.1016/S1046-5928(02)00650-2.
[16]
Galiano, L.; Ding, F.; Veloro, A.M.; Blackburn, M.E.; Simmerling, C.; Fanucci, G.E. Drug pressure selected mutations in HIV-1 protease alter flap conformations. J. Am. Chem. Soc. 2009, 131, 430–431.
[17]
Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. In Methods in Enzymology; Carter, C.W., Sweet, R.M., Eds.; Academic Press, Inc.: New York, NY, USA, 1997; Volume 276, pp. 307–326.
[18]
Collaborative Computational Project Number 4. The CCP4 suite: Programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 1994, 50, 760–763, doi:10.1107/S0907444994003112.
[19]
Arnold, K.; Bordoli, L.; Kopp, J.; Schwede, T. The SWISS-MODEL workspace: A web-based environment for protein structure homology modelling. Bioinformatics 2006, 22, 195–201, doi:10.1093/bioinformatics/bti770.
Darden, T.; York, D.; Pedersen, L. Particle mesh ewald - an N.Log(N) method for ewald sums in large systems. J. Chem. Phys. 1993, 98, 10089–10092, doi:10.1063/1.464397.
[22]
Hazuda, D.J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J.A.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; Miller, M.D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287, 646–650.
[23]
Baker, N.A.; Sept, D.; Joseph, S.; Holst, M.J.; McCammon, J.A. Electrostatics of nanosystems: Application to microtubules and the ribosome. Proc. Natl. Acad. Sci. USA 2001, 98, 10037–10041.
Sitkoff, D.; Sharp, K.A.; Honig, B. Accurate calculation of hydration free-energies using macroscopic solvent models. J. Phys. Chem. 1994, 98, 1978–1988.
